Purple Biotech (PPBT) has released an update.
Purple Biotech, listed as PPBT on NASDAQ/TASE, has entered a robust phase with multiple clinical data readouts expected in 2024 for its pioneering oncology drugs, including a promising first-in-class CEACAM1 inhibitor, CM24, targeting pancreatic cancer. The company highlights a strong cash position with sufficient runway into Q1 2025 and a global operational model. Its pipeline focuses on addressing cancers with significant unmet medical needs, leveraging its tri-specific immuno-engagers platform and other innovative therapies.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
